𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Etanercept no additional benefit in Wegener's granulomatosis

Book ID
120854442
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2005
Weight
120 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Limited versus severe Wegener's granulom
Limited versus severe Wegener's granulomatosis: Baseline data on patients in the Wegener's granulomatosis etanercept trial
✍ John H. Stone πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 1 views

## Abstract ## Objective To report baseline data on 180 patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET), and to examine demographic and clinical differences between patients with limited disease and those with severe disease. ## Methods Definitions of limit

Solid malignancies among patients in the
Solid malignancies among patients in the Wegener's granulomatosis etanercept trial
✍ John H. Stone; Janet T. Holbrook; Matthew A. Marriott; Andrea K. Tibbs; Lourdes πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 240 KB πŸ‘ 1 views

## Abstract ## Objective Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF). During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo‐controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more